(Q45022889)

English

Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Donna S Cox

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Neal S Kleiman

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Duane A Boyle

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jagadeesh Aluri

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

L Gerald Parchman

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Frederick Holdbrook

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Michael J Fossler

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

981-990

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

The role of thrombin inhibition during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

A guide to drug use during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Antithrombotic therapy in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

The role of low-molecular-weight heparin in the management of acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Heparin, bivalirudin, and reduction of complications during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Selective inhibition of coagulation factors: advances in antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

A synopsis of the clinical uses of argatroban

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270004267651

21 January 2018

Identifiers

10.1177/0091270004267651

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45022889&oldid=2144102199"